|
|
|
| Antimicrobial Resistance of Helicobacter Pylori Eradication in Chengde Area |
| HAO Xin, LI Jainhui |
| The Central Hospital of Chengde, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To investigate the antimicrobial resistance of Helicobacter pylori eradication in Chengde area and to explore the related treatment protocols. Method: Gastric mucosa specimens of 1036 cases of patents with Hp infection by endoscopy from March 2014 to December 2016 in Chengde Central Hospital, were cultured for Hp, 448 strains of clinic isolates were obtained, 9 kinds of antibacterial drug susceptibility test were taken to analyze drug resistance. Result: The sensitivity of amoxiciuim, amoxiciuim/clavulanute potassium and clarithromycin for the Chengde area's Hp was high, therefore the drug resistance rate was lower. Conclusion: Amoxicilln, amoxicilln/clarithromycin and clarithromycin can continue to be the top choice for the eradication of Hp in Chengde area. Tetracycline, furazolidone, levoifloxacin and moxifioxacin can be used as second-line drugs and the remedial treatment or treatment protocols again.
|
|
|
|
|
|
[1] 贺降福,滕小军.幽门螺旋杆菌与胃黏膜相关淋巴瘤[J].医学新知杂志,2008,18(2):104~106.
[2] 蓝菊慧.幽门螺旋杆菌所致消化性溃疡的发病机制和治疗近况[J].临床合理用药,2012,2(5):161~163.
[3] 张雪梅.胃癌患者幽门螺旋杆菌的感染情况分析及耐药性分析[J].中国病原生物学杂志,2016,11(4):362~364.
[4] 苏青,徐三平.幽门螺旋杆菌的研究进展[J].临床消化病杂志,2014,26(3):132~133.
[5] 中华医学会消化病学分会幽门螺旋杆菌学组/全国幽门螺旋杆菌研究协作组[J].第四次全国幽门螺旋杆菌感染处理共识报告,中华消化杂志,2012,32(10):655~661.
[6] 李娜,聂占国.幽门螺旋杆菌对抗生素耐药现状及其机制研究进展[J].山东医药,2013,53(16):85~88.
[7] 陈梁,彭孝纬.临床分离的幽门螺旋杆菌的多重耐药性的相关分析[J].2013,14(10):756~757. |
|
|
|
2017, Vol. 23 
